圣农发展(002299.SZ):约45.37万股限制性股票解除限售条件成就
格隆汇 3 月 4日丨圣农发展(002299.SZ)公布,公司于2021年3月4日召开第五届董事会第二十一次会议和第五届监事会第二十次会议,审议并通过了《关于2019年限制性股票激励计划首次授予的限制性股票第一个解除限售期解除限售条件成就的议案》,除1名已离职激励对象彭伟峰涉及的约1.11万股限制性股票尚未办理回购注销手续、不予解除限售外,此次可解除限售的激励对象人数为217人,共涉及可解除限售的限制性股票数量为约45.37万股,占目前公司股本总额约12.44亿股的比例为0.0365%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.